ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,457Medicare Part D Prescriptions Filled, Including Refills

Rank: 31 out of 487

$552K Total Retail Price of All Prescriptions

Rank: 29 out of 487

386 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Idaho
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 386 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 386 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 7,194 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Idaho
LEVOTHYROXINE SODIUM 400 324 1 1
FUROSEMIDE 354 284 2 7
OMEPRAZOLE 347 310 3 2
HYDROCODONE-ACETAMINOPHEN 248 168 S3 4 3
LISINOPRIL 245 201 5 5
SIMVASTATIN 222 182 6 4
AMLODIPINE BESYLATE 220 197 7 6
POTASSIUM CHLORIDE 214 157 8 10
CITALOPRAM HBR 175 156 9 12
TRAMADOL HCL 173 149 10 19
GABAPENTIN 158 147 11 13
WARFARIN SODIUM 156 128 12 11
ATENOLOL 135 120 13 23
LOSARTAN POTASSIUM 135 135 13 16
GLIMEPIRIDE 132 91 15 35
METOPROLOL SUCCINATE 130 99 16 15
LOVASTATIN 126 88 17 30
LISINOPRIL-HYDROCHLOROTHIAZIDE 105 92 18 24
FENTANYL 103 80 S2 19 36
HYDROCHLOROTHIAZIDE 102 102 20 9
MELOXICAM 97 75 21 26
ZOLPIDEM TARTRATE 95 61 22 14
ATORVASTATIN CALCIUM 94 36 23 18
METFORMIN HCL ER 93 79 24 31
TRAZODONE HCL 90 64 25 22
VENLAFAXINE HCL ER 90 80 25 55
ALENDRONATE SODIUM 88 71 27 27
SERTRALINE HCL 87 66 28 21
METFORMIN HCL 81 62 29 8
ALLOPURINOL 76 55 30 29
TRIAMTERENE-HCTZ 72 54 31 49
CARVEDILOL 71 47 32 32
MIRTAZAPINE 70 58 33 59
PAROXETINE HCL 64 55 34 51
FLUOXETINE HCL 64 51 34 28
KLOR-CON M20 63 49 36 83
DILTIAZEM 24HR CD 63 63 36 98
PREMARIN 62 38 R 38 89
ADVAIR DISKUS 61 50 39 46
DONEPEZIL HCL 61 49 39 38
FLUTICASONE PROPIONATE 61 43 39 33
POLYETHYLENE GLYCOL 3350 59 41 42 56
LOSARTAN-HYDROCHLOROTHIAZIDE 58 47 43 52
SPIRIVA 57 51 44 48
METOPROLOL TARTRATE 56 48 45 17
MORPHINE SULFATE ER 50 0 S2 46 54
ACTOS 50 0 46 88
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 23, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.